Aytu BioPharma Statistics
Total Valuation
Aytu BioPharma has a market cap or net worth of $24.36 million. The enterprise value is $16.44 million.
Important Dates
The last earnings date was Tuesday, February 3, 2026, after market close.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aytu BioPharma has 10.73 million shares outstanding. The number of shares has increased by 38.73% in one year.
| Current Share Class | 10.73M |
| Shares Outstanding | 10.73M |
| Shares Change (YoY) | +38.73% |
| Shares Change (QoQ) | -48.47% |
| Owned by Insiders (%) | 5.13% |
| Owned by Institutions (%) | 9.79% |
| Float | 7.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.29 |
| Forward PS | 0.82 |
| PB Ratio | 1.72 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.26 |
| EV / EBITDA | 4.08 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of 1.56.
| Current Ratio | 1.16 |
| Quick Ratio | 0.93 |
| Debt / Equity | 1.56 |
| Debt / EBITDA | 5.01 |
| Debt / FCF | n/a |
| Interest Coverage | -0.15 |
Financial Efficiency
Return on equity (ROE) is -109.23% and return on invested capital (ROIC) is -0.61%.
| Return on Equity (ROE) | -109.23% |
| Return on Assets (ROA) | -0.22% |
| Return on Invested Capital (ROIC) | -0.61% |
| Return on Capital Employed (ROCE) | -0.73% |
| Weighted Average Cost of Capital (WACC) | 7.87% |
| Revenue Per Employee | $754,699 |
| Profits Per Employee | -$294,494 |
| Employee Count | 83 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 2.10 |
Taxes
In the past 12 months, Aytu BioPharma has paid $315,000 in taxes.
| Income Tax | 315,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +51.33% in the last 52 weeks. The beta is 0.36, so Aytu BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | +51.33% |
| 50-Day Moving Average | 2.51 |
| 200-Day Moving Average | 2.21 |
| Relative Strength Index (RSI) | 37.85 |
| Average Volume (20 Days) | 86,938 |
Short Selling Information
The latest short interest is 548,197, so 5.11% of the outstanding shares have been sold short.
| Short Interest | 548,197 |
| Short Previous Month | 542,708 |
| Short % of Shares Out | 5.11% |
| Short % of Float | 7.23% |
| Short Ratio (days to cover) | 4.39 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of $62.64 million and -$24.44 million in losses. Loss per share was -$3.02.
| Revenue | 62.64M |
| Gross Profit | 41.87M |
| Operating Income | -413,000 |
| Pretax Income | -24.24M |
| Net Income | -24.44M |
| EBITDA | 4.03M |
| EBIT | -413,000 |
| Loss Per Share | -$3.02 |
Full Income StatementBalance Sheet
The company has $30.03 million in cash and $22.10 million in debt, with a net cash position of $7.92 million or $0.74 per share.
| Cash & Cash Equivalents | 30.03M |
| Total Debt | 22.10M |
| Net Cash | 7.92M |
| Net Cash Per Share | $0.74 |
| Equity (Book Value) | 14.20M |
| Book Value Per Share | 1.32 |
| Working Capital | 10.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$595,000 and capital expenditures -$103,000, giving a free cash flow of -$698,000.
| Operating Cash Flow | -595,000 |
| Capital Expenditures | -103,000 |
| Free Cash Flow | -698,000 |
| FCF Per Share | -$0.07 |
Full Cash Flow StatementMargins
Gross margin is 66.84%, with operating and profit margins of -0.66% and -39.02%.
| Gross Margin | 66.84% |
| Operating Margin | -0.66% |
| Pretax Margin | -38.70% |
| Profit Margin | -39.02% |
| EBITDA Margin | 6.43% |
| EBIT Margin | -0.66% |
| FCF Margin | n/a |
Dividends & Yields
Aytu BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.73% |
| Shareholder Yield | -38.73% |
| Earnings Yield | -100.32% |
| FCF Yield | -2.86% |
Analyst Forecast
The average price target for Aytu BioPharma is $9.33, which is 311.01% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.33 |
| Price Target Difference | 311.01% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 6, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 6, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Aytu BioPharma has an Altman Z-Score of -3.23 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.23 |
| Piotroski F-Score | 3 |
